Serum biomarkers identification by iTRAQ and verification by MRM: S100A8/S100A9 levels predict tumor-stroma involvement and prognosis in Glioblastoma

Despite advances in biology and treatment modalities, the prognosis of glioblastoma (GBM) remains poor. Serum reflects disease macroenvironment and thus provides a less invasive means to diagnose and monitor a diseased condition. By employing 4-plex iTRAQ methodology, we identified 40 proteins with...

Descripción completa

Detalles Bibliográficos
Autores principales: Arora, Anjali, Patil, Vikas, Kundu, Paramita, Kondaiah, Paturu, Hegde, A. S., Arivazhagan, A., Santosh, Vani, Pal, Debnath, Somasundaram, Kumaravel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391445/
https://www.ncbi.nlm.nih.gov/pubmed/30808902
http://dx.doi.org/10.1038/s41598-019-39067-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391445/
https://www.ncbi.nlm.nih.gov/pubmed/30808902
http://dx.doi.org/10.1038/s41598-019-39067-8

Ejemplares similares